

Special Issue

Innate Immunosurveillance of Cancer

Message from the Guest Editor

Innate immune cells are the first line of defense against cancer development and infections. These cells respond to initial perturbations in the tissue, which can result in either control or even prevention of tumor initiation and progression. But, as tumors develop immune evasive mechanisms, innate immune cells can also facilitate tumor progression and metastasis. Therefore, understanding the influence and mechanisms underlying both pro- and anti-tumor effects of the innate immune system is crucial in fighting cancer. This Special Issue will collect a series of reviews and original articles describing basic science, preclinical, and clinical investigations, covering all aspects of innate immune surveillance from tumor initiation, progression, and metastasis. Potential topics include but are not limited to tumor immune microenvironments with emphasis on innate immune cells, innate immune receptors and signaling, molecular mechanisms of innate immune evasion, engineering innate immune cells, novel immunotherapies, and mechanisms of resistance to immunotherapies.

Guest Editor

Dr. Venkateshwar G. Keshamouni

Department of Internal Medicine, Pulmonary & Critical Care Division,
Medical School, University of Michigan, Ann Arbor, MI 48109, USA

Deadline for manuscript submissions

closed (31 December 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/80537

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)